This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Therapeutic Areas
Therapeutic Areas
Race Oncology’s goal is to improve the lives of cancer patients around the world by advancing a novel approach to simultaneously better treating the cancer while protecting the cardiovascular system including the heart from chemotherapy.
Solid tumours
Bisantrene has proven clinical efficacy in a range solid tumour cancers and lower toxicity on the heart.
Bisantrene was studied in seven Phase 2 and Phase 3 breast cancer trials in the 1980s. A large Phase 3 trial demonstrated that bisantrene outperformed mitoxantrone and had a similar overall survival of doxorubicin (current standard of care chemotherapeutic), but with significantly lower rates of serious damage to the heart (4% bisantrene, 12% mitoxantrone, 23% doxorubicin).
Recent discoveries made by Race Oncology scientists have also identified that in preclinical models, bisantrene added to commonly used anticancer chemotherapy can better treat cancers while protecting the heart from the permanent damage caused by chemotherapy.
Race will begin in 2024 a Phase 1 clinical trial of RC220 in patients with solid tumours where the use of an anthracycline is indicated. For further information on this trial please contact info@raceoncology.com.
Acute myeloid leukemia (AML)
Bisantrene has an extensive clinical history in treating AML and was approved in France for the treatment of relapsed or refractory (R/R) AML in 1988.
Race Oncology in collaboration with the Sheba Medical Center in Israel has run two Phase 2 clinical trials in R/R AML patients using RC110 (bisantrene). The first, completed in 2020, demonstrated a 40% response rate in late-stage AML patients who had failed a median of three prior lines of treatment. The second, which reported interim results in 2023, demonstrated a 40% response in very advanced AML patients (median of four lines of prior treatment) when used in combination with fludarabine and clofarabine.
Race has announced a new collaboration with an Australian AML clinical team to undertake a new Phase 1/2 AML trial using RC220 in combination with oral decitabine as a low-intensity treatment for patients unable or unwilling to tolerate high intensity chemotherapy. This trial is expected to begin in late 2024/early 2025. For further information on this trial please contact info@raceoncology.com.
